Xenetic Biosciences, Inc. (XBIO) - Long-Term Debt to Capital

Corporate emblem and logo of Xenetic Biosciences Inc. (XBIO)

Xenetic Biosciences (XBIO) automates the creation of DNase-based oncology drugs via robotic screening, minimizing manual labor for biologists. The company is also developing a platform for vaccine optimization and immune management. This price chart reflects the dynamics of debt obligations, which currently stand at 0.00. High market confidence is driven by the success of the XCART system for personalized cell therapy and strict adherence to scientific standards.

xeneticbio.com - XBIO Long-Term Debt to Capital (period 07/04/2022 - 11/01/2026)

Analytical breakdowns for Xenetic Biosciences

- stock value and consensus price forecast:
Stock Quotes Xenetic Bio|XBIO - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Xenetic Biosciences, Inc.|XBIO - Total Company Value
- company book value details:
Equity per Share Xenetic Biosciences|XBIO - Book Capitalization|Market Cap to Net Assets Ratio xeneticbio.com|XBIO - Company Total Assets
- company liabilities and liquidity data:
Debt to Capital Xenetic Biosciences|XBIO - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Xenetic Bio|XBIO - Company Total Debt|Debt to Net Assets Ratio Xenetic Biosciences, Inc.|XBIO - Company Long-Term Debts|Company Current Liabilities Xenetic Biosciences|Quick Ratio xeneticbio.com
- financial results and valuation multiples details:
XBIO - Company Net Income
General company analysis:xeneticbio.com - XBIO
Original product of Xenetic Biosciences

Xenetic Biosciences (XBIO) occupies a narrow niche in the development of enzyme-based cancer treatments. By analyzing the share of long-term loans within the capital structure, an investor assesses the ratio of liabilities with a maturity of over one year to equity. This metric determines the degree of financial autonomy and reliance on borrowed funds. For a biotech firm dependent on external investment, a low debt level reduces bankruptcy risk in the event of clinical trial delays. The market views a minimal debt load as a guarantee of the company's stability.

Key competitors

Long-Term Debt to Equity Ratio BeiGene Ltd. (ONC)|Long-Term Debt to Capital HALO|Long-Term Debt to Capital Revolution Medicines Corp (RVMD)|Long-Term Debt to Equity Ascentage Pharma Group AAPG|CGON: Long-Term Debt to Capital Ratio|UroGen Pharma - Long-Term Debt to Capital|Bicara Therapeutics Inc (BCAX) - Long-Term Debt to Equity Ratio|PSNL: Long-Term Debt to Capital|Long-Term Liabilities to Capital Erasca Oncology (ERAS)|Long-Term Debt to Equity Delcath Systems, Inc.|YMAB: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio AURA (Aura Biosciences)|CADL (candeltx.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ARAY (Accuray Inc.)|SLS - Long-Term Debt to Equity Ratio|ACTU: Long-Term Debt to Equity Ratio|CTOR - Long-Term Debt to Capital|tuhurabio.com (HURA) - Long-Term Debt to Equity|Protara Therapeutics Inc - Long-Term Debt to Capital Coefficient|FATE (Fate Therapeutics Corp) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Aadi Bio WHWK|Long-Term Debt to Equity Ratio TCRX (TScan Therapeutics)|championsoncology.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital XBIT (XBiotech)|CEL-SCI Corp. (CVM) - Long-Term Liabilities to Capital|OSTX - Long-Term Debt to Equity|RADX (Radiopharm Theranostics Ltd) - Long-Term Debt to Capital Ratio|ARTV: Long-Term Debt to Capital|Long-Term Liabilities to Capital Adlai Nortye (ANL)|Long-Term Debt to Equity Ratio VERU|TPST (Tempest Therapeutics Inc) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital XLO|Ratio of Long-Term Indebtedness to Capital renovarobio.com|Long-Term Debt to Capital MURA (Mural Oncology)|KAPA - Long-Term Debt to Equity Ratio|OKUR: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient GDTC (CytoMed Therapeutics)|CRIS: Long-Term Debt to Capital|APLM (Apollomics) - Long-Term Debt to Equity|THAR (Tharimmune, Inc.) - Long-Term Debt to Capital|Advanced Biomed Corp (ADVB) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Genprex (GNPX)|CLDI - Long-Term Liabilities to Capital|Long-Term Debt to Equity Sunshine Biopharma SBFM|Ratio of Long-Term Indebtedness to Capital Salarius Pharma (SLRX)|Purple Biotech - Long-Term Debt to Capital|American Oncology Network (AONC) - Long-Term Debt to Equity Ratio|BGNE: Long-Term Debt to Capital|CKPT - Ratio of Long-Term Indebtedness to Capital|ELEV (Elevation Oncology, Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital iCAD Corp ICAD|Long-Term Debt to Equity Ikena Oncology, Inc. (IKNA)|notablelabs.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital VIRX (Viracta Therapeutics, Inc.)|MOR - Long-Term Debt to Equity Ratio|NAYA Bio - Long-Term Debt to Capital|Long-Term Liabilities to Capital Ascentage